Abbott Laboratories (ABT) Other Accumulated Expenses (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Other Accumulated Expenses data on file, last reported at $6.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 13.91% year-over-year to $6.4 billion; the trailing twelve-month figure through Mar 2026 stood at $6.4 billion (up 13.91% YoY), and the FY2025 full-year result was $5.8 billion, up 13.01% from the prior year.
• Other Accumulated Expenses improved to $6.4 billion in Q1 2026, from $5.8 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $6.4 billion in Q1 2026 to a low of $5.1 billion in Q2 2024.
• A 5-year average of $5.5 billion and a median of $5.5 billion in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses slipped 9.34% in 2024 and gained 13.91% in 2026, its largest moves.
• Tracing ABT's Other Accumulated Expenses over 5 years: stood at $5.8 billion in 2022, then decreased by 7.24% to $5.4 billion in 2023, then retreated by 5.15% to $5.1 billion in 2024, then rose by 13.01% to $5.8 billion in 2025, then gained by 9.76% to $6.4 billion in 2026.
• Business Quant data shows ABT's Other Accumulated Expenses at $6.4 billion in Q1 2026, $5.8 billion in Q4 2025, and $5.9 billion in Q3 2025.